Got a great short conversation for you today, guys.

I'm just back from London, met with my friend,

Assim al-Hatra, cardiologist, Crusader.

And he was presenting at a press conference,

G.B News were there, et cetera.

His new paper looking at the cost-benefit

of the mass medications for the viral challenge.

And I think you'll find it really interesting.

We had a short conversation.

We were time limited, but we kind of packed it in there with the data and the reality.

And down below you'll see as well are his two published papers.

They're both related, peer reviewed in the Journal of Insulin Resistance.

And they're quite a read for the layperson

even they're not all heavy dense science very approachable and fully referenced so do enjoy those

and please do share them and open up the conversation and I think a lot more conversation is occurring

now so without further ado myself and Dr. Asim al-Hattra in London.

I'm delighted to have been able to come over to London, which I like, to the Emanuel Center

and meet again with Dr. Asim al-Hotra.

Always great to see you.

Absolutely.

And you were here today for your press release of two new papers relating to the COVID, not general vaccines, the COVID vaccine and the data that's emerging. So I read them. They're fantastic. First one goes through the kind of cost benefit and all the vaccine related content. And the second one looks more at the problem in the system as to why we ended up

with this kind of debacle so maybe I'll let you go ahead to see him and just pick some of your

...